Representative image NEW DELHI: Amid concerns over shortages of two critical cancer medicines, National Pharmaceutical Pricing Authority has approved a 50% hike in ceiling prices of Carboplatin and Cisplatin injections, citing escalating raw material costs and supply concerns.The regulator has also revised prices of anti-tetanus immunoglobulin and three key childhood vaccines to ensure their continued availability. The decision, for which a gazette notification has been issued, was taken at NPPA’s 147th meeting on Thursday, where the authority invoked its extraordinary powers under Para 19 of the Drug Price Control Order (DPCO), 2013, to revise prices of formulations considered critical for public health.NPPA said concerns over shortages of Carboplatin and Cisplatin had been raised on multiple platforms and manufacturers had reported sharp increases and volatility in prices of active pharmaceutical ingredients. The authority said it had also held discussions with manufacturers to address supply concerns and ensure continued availability of the drugs.Carboplatin and Cisplatin are among the most widely used chemotherapy medicines and are used in first-line treatment for several cancers. The regulator said while affordability remained important, access to life-saving medicines could not be jeopardised by making their production commercially unviable.Accordingly, the ceiling price of Carboplatin 10 mg/ml injection has been increased from Rs 60.49 per ml to Rs 90.74 per ml, while the ceiling price of Cisplatin 1 mg/ml injection has been revised from Rs 7.26 per ml to Rs 10.89 per ml. The revised prices will be reviewed after six months, or earlier if required.The authority also approved a one-time 50% increase in ceiling prices of anti-tetanus immunoglobulin 250 IU and 500 IU injections after manufacturers flagged viability concerns.In addition, NPPA revised ceiling prices of BCG, measles and measles-rubella vaccines, citing their public health importance and the limited number of manufacturers.Of the 82 applications seeking upward price revisions under Para 19 of DPCO, only four formulations were approved, while 78 were deferred for additional information. The regulator said the move aimed to prevent shortages and ensure supplies of life-saving medicines and vaccines.Get the latest India news and live updates. Download the TOI App.About the AuthorAnuja JaiswalAnuja Jaiswal is a Senior Assistant Editor at The Times of India, with an impressive 18-year career in narrative journalism. She specializes in health and heritage reporting, expertly simplifying complex health information to make it engaging and understandable for readers. Her deep dives into heritage topics are well-researched, resulting in captivating narratives that resonate with her audience. Over the years, she has worked in Chandigarh, Chhattisgarh and West UP, gaining diverse on-ground experience that shapes her storytelling.Read MoreEnd of ArticleFollow Us On Social MediaVideosIndia’s ‘Eye In The Sky’ Netra AEW&C To Receive Final Operational Clearance This MonthKolkata Government Building Fire Destroys 4,000 EVMs; Forensic Investigation UnderwayIndia On Border Alert As Jamaat’s Protest Call Raises Fresh Questions Over Bangladesh StabilityAbhishek Banerjee Replies to Kalyan Banerjee’s Remarks, Says He Will Not Speak Against HimSpaceX lists at $1.75 trillion — here’s what Indian investors need to know before buyingAIUDF To Challenge Assam UCC In Court, Says Law Is Not Truly UniformAI-171 Crash Probe Continues A Year Later; AAIB Says Final Report Yet To Be CompletedAIMIM Eyes Major Expansion In UP, Opens Door To Possible BSP Alliance | WatchIndira Gandhi Lost Her Party Twice — And Came Back Both Times. Can Mamata Banerjee?PM Modi To Showcase 120 Top Indian Startups In France; Global Investors Eye Opportunities123PhotostoriesSmriti Irani, Disha Vakani to Bharti Singh: Actresses who shot for their TV shows during pregnancyThink Osteoporosis is a women’s disease? Here’s why men should be concerned tooFrom Jeff Bezos and MacKenzie Scott to Arjun Rampal and Mehr Jesia: 7 famous celebrities who got divorced after 20+ years of marriageFrom headaches to mobile phones: Brain tumour myths doctors want you to stop believingFrom Sujni to Manjusha: 10 artworks of Bihar and places travellers should visit to find themPower rituals for Gen Z based on your birth dateBefore R Praggnanandhaa and Vaishali became the ‘Golden Chess Siblings’; their mother built the foundation: How Nagalakshmi nurtured two grandmastersScientists discovered this 7-minute trick that completely resets a stressed brainSpanish love proverb of the day: “Love is blind, but the neighbours are not”Harmanpreet Kaur, Indian women cricket team captain’s, home in Moga, Punjab is a reflection of her humble roots, family values and cricketing success123Hot PicksSpaceX IPOKick StreamerJaspal RanaShakiraMP Board 12 Supplementary ResultISC Revaluation ResultSpaceX IPONora FatehiVirat KohliTop TrendingTMC rebel MPTravis KelceSpaceX IPOFIFA World Cup 2026Women T20 World CupSean SticklandBharatiya Antariksh HackathonKerala SSLC Revaluation ResultUPSC result 2026CBSE Class 10 Second Board Result
NEW DELHI: Amid concerns over shortages of two critical cancer medicines, National Pharmaceutical Pricing Authority has approved a 50% hike in ceiling prices of Carboplatin and Cisplatin injections, citing escalating raw material costs and supply concerns.The regulator has also revised prices of anti-tetanus immunoglobulin and three key childhood vaccines to ensure their continued availability. The decision, for which a gazette notification has been issued, was taken at NPPA’s 147th meeting on Thursday, where the authority invoked its extraordinary powers under Para 19 of the Drug Price Control Order (DPCO), 2013, to revise prices of formulations considered critical for public health.NPPA said concerns over shortages of Carboplatin and Cisplatin had been raised on multiple platforms and manufacturers had reported sharp increases and volatility in prices of active pharmaceutical ingredients. The authority said it had also held discussions with manufacturers to address supply concerns and ensure continued availability of the drugs.Carboplatin and Cisplatin are among the most widely used chemotherapy medicines and are used in first-line treatment for several cancers. The regulator said while affordability remained important, access to life-saving medicines could not be jeopardised by making their production commercially unviable.Accordingly, the ceiling price of Carboplatin 10 mg/ml injection has been increased from Rs 60.49 per ml to Rs 90.74 per ml, while the ceiling price of Cisplatin 1 mg/ml injection has been revised from Rs 7.26 per ml to Rs 10.89 per ml. The revised prices will be reviewed after six months, or earlier if required.The authority also approved a one-time 50% increase in ceiling prices of anti-tetanus immunoglobulin 250 IU and 500 IU injections after manufacturers flagged viability concerns.In addition, NPPA revised ceiling prices of BCG, measles and measles-rubella vaccines, citing their public health importance and the limited number of manufacturers.Of the 82 applications seeking upward price revisions under Para 19 of DPCO, only four formulations were approved, while 78 were deferred for additional information. The regulator said the move aimed to prevent shortages and ensure supplies of life-saving medicines and vaccines.
